Related Experiment Video
Updated: May 28, 2025

06:56
Author Spotlight: Advancing Cardiac Procedure Testing Prior to Embarking on Large Animal Studies
Published on: August 25, 2023
878
Rethinking mechanical heart valves in the aortic position: new paradigms in design and testing.
Sreyashi Chakraborty1, Melinda G Simon1, Alessandro Bellofiore1
1Biomedical Engineering Department, San José State University, San Jose, CA, United States.
Frontiers in Cardiovascular Medicine
|February 14, 2025
Summary
Bileaflet mechanical heart valves (MHV) offer durability but risk blood clots. Future MHV designs aim for better thromboresistance, reducing the need for anticoagulants.
Area of Science:
- Biomedical Engineering
- Cardiovascular Research
- Materials Science
Background:
- Bileaflet mechanical heart valves (MHV) are crucial for aortic valve replacement, especially in specific demographics.
- Despite durability, MHV patients face a higher risk of thromboembolic complications.
- Current MHV technology necessitates lifelong anticoagulant therapy.
Purpose of the Study:
- To review emerging paradigms in MHV design, materials, and surface modifications.
- To address challenges in developing next-generation MHVs with improved thromboresistance.
- To explore advancements for MHVs that reduce or eliminate the need for anticoagulation.
Main Methods:
- Review of current literature on MHV design, materials, and surface modifications.
- Analysis of challenges in MHV innovation, including performance, biocompatibility, and thrombosis mechanisms.
- Discussion of experimental and numerical approaches for evaluating MHV hemodynamics and thrombogenicity.
Main Results:
- Emerging design strategies, materials, and surface modifications show promise for enhancing MHV thromboresistance.
- Limited understanding of MHV thrombosis mechanisms and inadequate testing methodologies hinder innovation.
- Advanced experimental and computational fluid dynamics offer pathways to better assess MHV performance and clotting risks.
Conclusions:
- Next-generation MHVs must prioritize thromboresistance to minimize anticoagulant dependence.
- Overcoming design, biocompatibility, and testing challenges is critical for MHV advancement.
- Further research into flow-induced thrombosis and improved evaluation methods will drive the development of safer, more effective MHVs.

